Compare TRVG & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | OABI |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Germany | United States |
| Employees | 893 | 89 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.4M | 391.4M |
| IPO Year | 2015 | N/A |
| Metric | TRVG | OABI |
|---|---|---|
| Price | $5.27 | $2.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.95 | ★ $4.50 |
| AVG Volume (30 Days) | 120.5K | ★ 644.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | $52.42 |
| Revenue Next Year | $8.42 | $64.69 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $1.32 |
| 52 Week High | $5.70 | $2.79 |
| Indicator | TRVG | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 67.63 | 40.92 |
| Support Level | $2.78 | $1.75 |
| Resistance Level | $5.70 | $2.22 |
| Average True Range (ATR) | 0.35 | 0.18 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 64.31 | 9.17 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.